Figure 3. Concentrations of ferritin, interleukin-6 (IL-6) and interferongamma (IFNγ) in the circulation of seven patients before the start of treatment with LMWH and of eight patients more than 3 days after start of the treatment with LMWH. Concentrations from four patients with mild COVID-19 are provided as controls. Only significant comparisons are provided.
